Radar›Companies›Pharmaceutical Preparations Stocks in USA: Revenue Cohort 18
United States pharmaceutical preparations industry landscape illustrating listed-company operations, infrastructure and market activity
Prism Finance USA · comparison snapshot

Pharmaceutical Preparations Stocks in USA: Revenue Cohort 18

A five-company pharmaceutical preparations cohort selected by latest filing revenue, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 28 August 2026Not investment adviceRanked by Prism readiness
Readiness leaderScynexis · 42
Strongest available pathRoivant Sciences · +277.7%
Widest latest marginScynexis · -41.8%
Companies compared5 · U.S.-listed
01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1SCYX · Nasdaq

Scynexis

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 1999Jersey City, New Jersey$53.6M market cap
View full Companies Radar profile
42Cautious
Snapshot price$5.39as of page date
Monthly-close return-89.4%five-year window
FY2025 revenue$0.02BSCYNEXIS INC
Net margin-41.8%FY2025
P/E snapshot-2.3xone ratio, not a verdict
Prism attention17.3%share across these five
Filing track recordRevenue, USD billions
+56.5%
$0$0.0B$0.1B$0.1BFY2021: $0.013BFY2022: $0.005BFY2023: $0.140BFY2024: $0.004BFY2025: $0.021B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 11.8%
52-week position27% through range
$3.53$10.48
News mentions746
Community mentions60partial coverage
U.S.-scope patents323
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal39/100
Management stability90/100
Market position8/100
Capital-event signal60/100
Innovation pulse9/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 2 asset-acquisition events and 6 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 5 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2ROIV · Nasdaq

Roivant Sciences

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2014New York City, New York$25.07B market cap
View full Companies Radar profile
40Cautious
Snapshot price$34.71as of page date
Monthly-close return+277.7%five-year window
FY2024 revenue$0.03BRoivant Sciences Ltd.
Net margin-592.0%FY2024
P/E snapshot-20.2xone ratio, not a verdict
Prism attention50.9%share across these five
Filing track recordRevenue, USD billions
-47.4%
$0$0.0B$0.1B$0.1BFY2022: $0.055BFY2023: $0.125BFY2024: $0.029B202220232024
FY2022–FY2024 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -27.5%
52-week position87% through range
$11.94$37.97
News mentions2.2K
Community mentions35partial coverage
U.S.-scope patents1
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal24/100
Management stability90/100
Market position21/100
Capital-event signal73/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 18 M&A involvements, 4 asset-acquisition events and 5 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3NXTC · Nasdaq

NextCure

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2015New Haven, Connecticut$27.9M market cap
View full Companies Radar profile
38Cautious
Snapshot price$6.09as of page date
Monthly-close return-93.4%five-year window
FY2021 revenue$0.02BNextCure, Inc.
Net margin-310.1%FY2021
P/E snapshot-1.1xone ratio, not a verdict
Prism attention9.1%share across these five
Filing track recordRevenue, USD billions
+252.6%
$0$0.0B$0.0B$0.0BFY2019: $0.006BFY2020: $0.022BFY2021: $0.022B201920202021
FY2019–FY2021 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 87.8%
52-week position32% through range
$1.55$15.74
News mentions393
Community mentions11partial coverage
U.S.-scope patents77
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal47/100
Management stability90/100
Market position0/100
Capital-event signal40/100
Innovation pulse0/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4CUE · Nasdaq

Cue Biopharma

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2015Cambridge, Massachusetts$202.5M market cap
View full Companies Radar profile
32Cautious
Snapshot price$27.88as of page date
Monthly-close return-92.2%five-year window
FY2025 revenue$0.03BCue Biopharma, Inc.
Net margin-96.9%FY2025
Prism attention11.8%share across these five
Filing track recordRevenue, USD billions
+83.8%
$0$0.0B$0.0B$0.0BFY2021: $0.015BFY2022: $0.001BFY2023: $0.005BFY2024: $0.009BFY2025: $0.027B20212022202320242025
FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 16.4%
52-week position57% through range
$4.98$45.50
News mentions507
Community mentions0partial coverage
U.S.-scope patents491
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal39/100
Management stability78/100
Market position0/100
Capital-event signal25/100
Innovation pulse3/100
Management signal

No leadership-churn flag in the model; 6 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 1 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5TRDA · Nasdaq

Entrada Therapeutics

A U.S.-listed issuer classified by the SEC in Pharmaceutical Preparations

Founded 2016Boston, Massachusetts$272.6M market cap
View full Companies Radar profile
30Cautious
Snapshot price$7.00as of page date
Monthly-close return-69.6%five-year window
FY2025 revenue$0.03BEntrada Therapeutics, Inc.
Net margin-565.5%FY2025
P/E snapshot-2.2xone ratio, not a verdict
Prism attention10.9%share across these five
Filing track recordRevenue, USD billions
-80.3%
$0$0.1B$0.1B$0.2BFY2023: $0.129BFY2024: $0.211BFY2025: $0.025B202320242025
FY2023–FY2025 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -55.6%
52-week position17% through range
$5.02$16.45
News mentions469
Community mentions1partial coverage
U.S.-scope patents128
Prism Insights

What sits behind the readiness signal

Observed risk 0/100higher means more observed risk
Earnings signal32/100
Management stability90/100
Market position0/100
Capital-event signal15/100
Innovation pulse5/100
Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Roivant Sciences
+277.7%
Entrada Therapeutics
-69.6%
Scynexis
-89.4%
Cue Biopharma
-92.2%
NextCure
-93.4%

Latest revenue

USD billions, official filing scope shown on each company card.

Roivant Sciences
$0.03B
Cue Biopharma
$0.03B
Entrada Therapeutics
$0.03B
NextCure
$0.02B
Scynexis
$0.02B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Scynexis
-41.8%
Cue Biopharma
-96.9%
NextCure
-310.1%
Entrada Therapeutics
-565.5%
Roivant Sciences
-592.0%

Prism news attention

Normalized share across these five names; attention is not quality.

Roivant Sciences
50.9%
Scynexis
17.3%
Cue Biopharma
11.8%
Entrada Therapeutics
10.9%
NextCure
9.1%
03 · Prism readout

What the signals say—and what they do not

The headline share is normalized pharmaceutical preparations news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Roivant Sciences leads the conversation

It holds 50.9% of measured pharmaceutical preparations news attention and also carries the basket's largest revenue base at $0.03B.

Price path

Roivant Sciences leads the available price paths

Its monthly-close return is +277.7% for the five-year window. At the other end, NextCure is -93.4% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Scynexis has the widest latest margin

Its FY2025 net margin is -41.8%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Roivant Sciences shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -20.2x while its five-year window price return is +277.7%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · ROIV

Roivant Sciences

2,187available Prism news records

Prism top themes

Price action & investor response
100
Capital allocation & transactions
43
Legal, arbitration & regulatory
21
Earnings & financial performance
20
Leadership & governance
19

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-1.8%319 latest 12m vs 325 prior 12m
2024-01: 47 mentions2024-02: 20 mentions2024-03: 22 mentions2024-04: 23 mentions2024-05: 30 mentions2024-06: 9 mentions2024-07: 4 mentions2024-08: 9 mentions2024-09: 22 mentions2024-10: 7 mentions2024-11: 95 mentions2024-12: 27 mentions2025-01: 32 mentions2025-02: 75 mentions2025-03: 19 mentions2025-04: 14 mentions2025-05: 14 mentions2025-06: 7 mentions2025-07: 19 mentions2025-08: 27 mentions2025-09: 46 mentions2025-10: 14 mentions2025-11: 34 mentions2025-12: 17 mentions2026-01: 13 mentions2026-02: 31 mentions2026-03: 32 mentions2026-04: 43 mentions2026-05: 36 mentions2026-06: 7 mentions2024-012026-06

Machine-classified coverage tone

75.6% positive-5.0 pp vs preceding four quarters
24Q3
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stock performance 45stock price 10stock surge 8stock indices 8market rally 8patent litigation 8angiogenesis inhibitors 7immunotherapy 6

Keyword tag occurrences in available Prism news records.

Coverage: 2014-12-23–2026-06-19 · trend and themes shown through 2026-06
05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

SCYX

Scynexis

60 mentions
Stock and valuation
35
Products, pricing and logistics
6

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 60 records remained after filtering.

ROIV

Roivant Sciences

35 mentions
Stock and valuation
12
Products, pricing and logistics
4
Workplace and hiring
1

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 35 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

SCYX

Scynexis

through 2025-11-06
Business contracts 6Earnings releases 6Company announcements 5Listing / IPO 2Lawsuits 1
  1. Company announcements

    On September 30, 2025, the Company announced positive results from a Phase 1 SAD/MAD study of SCY-247, its second-generation triterpenoid antifungal under development for the treatment and prevention of invasive fungal infections.

  2. Earnings releases

    SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines ... today reported financial results for the year ended December 31, 2024.

  3. Regulatory

    cleared by the U.S. FDA for vulvovaginal candidiasis (VVC) and for reduction in the incidence of recurrent VVC.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

ROIV

Roivant Sciences

through 2025-12-18
Earnings releases 5Asset acquisitions 3Leadership changes 3M&A 3Listing / IPO 2
  1. M&A

    Roivant Sciences Ltd. acquired 16,666,666 shares in a single open-market purchase on Dec. 12, 2025, for a transaction value of ~$350.0 million at $21.00 per share.

  2. Earnings releases

    Roivant reported that its revenue for the period was slightly under $2.2 billion, which was quite some distance down from the nearly $8 billion it reaped in the same quarter last year. The situation was hardly better on the bottom line, as the company flipped to a more than $223 million ($0.33 per share) generally accepted accounting principles (GAAP) net loss from the year-ago profit of $95 million.

  3. Leadership changes

    Rakhi Kumar resigned from her roles as the Principal Accounting Officer of Roivant Sciences Ltd. and Chief Accounting Officer of its subsidiary, effective February 20, 2025.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

NXTC

NextCure

through 2026-03-31
Company announcements 3Earnings releases 3
  1. Earnings releases

    NextCure N/A N/A -$55.84 million ($20.00) -0.54

  2. Company announcements

    Earlier in July, NextCure enacted a 1-for-12 reverse stock split, and its shares began trading on an adjusted basis.

  3. Company announcements

    The surge in NextCure’s stock value came after the company presented new preclinical data for NC605, a potential treatment for brittle bone disease.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

CUE

Cue Biopharma

through 2026-04-22
Leadership changes 13Earnings releases 8Listing / IPO 2Board updates 1Company announcements 1
  1. Company announcements

    Cue Biopharma, Inc. (Nasdaq: CUE ), a clinical-stage biopharmaceutical company ... today announced that it will implement a 1-for-30 reverse stock split of the issued shares of the company’s common stock, effective at 5:00 p.m. Eastern Time on April 23, 2026.

  2. Board updates

    The six nominees were elected as directors.

  3. Earnings releases

    Cue Biopharma (NASDAQ:CUE – Get Free Report) last posted its quarterly earnings data on Monday, March 16th.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

TRDA

Entrada Therapeutics

through 2024-03-13
Earnings releases 4Lawsuits 1Leadership changes 1
  1. Earnings releases

    Entrada Therapeutics missed estimated earnings by -71.0%, reporting an EPS of $-0.29 versus an estimate of $-0.17.

  2. Leadership changes

    Entrada Therapeutics announced that Nathan Dowden, current Chief Operating Officer of Entrada Therapeutics, has been promoted to President and Chief Operating Officer, effective as of January 1, 2024.

  3. Lawsuits

    Pomerantz LLP is investigating claims on behalf of investors of Entrada Therapeutics, Inc. ("Entrada" or the "Company") (NASDAQ: TRDA).

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Pharmaceutical Preparations Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary pharmaceutical preparations news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

pharmaceutical industry

36 sources100.0% extraction confidence
2011 extracted base$66.70B
2016 extracted forecast$42.00B–$70.00B
Implied source CAGR9.5%
Macro and micro trends driving the industry's futureR&D expenditure and leading therapeutic areasGrowth opportunities

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, India, China, U.S.. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Pharmaceutical Preparations news pulse

55,282available Prism news records
Latest 12m volume+3.4%24052 vs 23272 records
Positive classified tone65.3%+6.0 pp vs prior four quarters
2024-01: 2,385 mentions2024-02: 1,423 mentions2024-03: 1,374 mentions2024-04: 1,289 mentions2024-05: 1,487 mentions2024-06: 1,819 mentions2024-07: 1,355 mentions2024-08: 1,609 mentions2024-09: 1,720 mentions2024-10: 1,625 mentions2024-11: 1,853 mentions2024-12: 1,522 mentions2025-01: 2,799 mentions2025-02: 2,971 mentions2025-03: 2,174 mentions2025-04: 2,142 mentions2025-05: 1,683 mentions2025-06: 1,142 mentions2025-07: 1,921 mentions2025-08: 3,922 mentions2025-09: 2,081 mentions2025-10: 1,648 mentions2025-11: 1,720 mentions2025-12: 1,496 mentions2026-01: 1,701 mentions2026-02: 3,364 mentions2026-03: 1,972 mentions2026-04: 2,867 mentions2026-05: 218 mentions2024-012026-05
24Q4
25Q1
25Q2
25Q3
25Q4
26Q1
26Q2
26Q3

Available U.S.-primary Prism records matching pharmaceutical, preparation. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

drug pricing and reimbursement strategies
6,223
snowstorm and blizzard alerts
6,121
pharmaceutical marketing and sales strategies
6,014
winter weather preparedness
5,925
generic drug development and market trends
3,700
healthcare economics and market access
3,498

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

ice storm preparation 6,522snowstorm advisory 5,649cold weather readiness 5,010heavy snow warning 4,972winter storm alert 4,355snow accumulation alert 4,114life-threatening weather 2,915severe weather warning 2,905

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

Macro and micro trends driving the industry's future

36 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card
Opportunity · demand

drug pricing and reimbursement strategies

6,223 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata
Opportunity · innovation

Innovation and product activity

5,689 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule
Caution · market restraint

regulatory changes

5,709 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata
Caution · news pulse

Coverage growth can reverse

+3.4% news volume

The latest 12 months contain 24,052 matched records versus 23,272 in the previous window.

Available Prism coverage through 2026-05-05
Caution · sentiment

Classified tone is not demand

65.3% positive · +6.0pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →
08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2834 (Pharmaceutical Preparations), selected as the first five names that pass all live publication gates from the latest filing revenue candidate pool ranked 86–93. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

  • Official annual filingsFY revenue history and latest profitability
  • U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
  • Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
  • Prism market-growth extractionDated third-party Pharmaceutical Preparations Industry in USA market benchmark with source-count, geography and confidence context
Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 28 August 2026.
09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions
Comparisons
Anomalies

NextCure has the widest attention-readiness rank gap

It ranks #5 by measured news attention (9.1%) and #3 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open NextCure in Companies Radar

NextCure shows a price-operating divergence to inspect

Its displayed filing-revenue change is +252.6% while its available monthly-close return is -93.4%. The signs differ, but the two measures cover different windows and do not establish causality.

Open NextCure in Companies Radar
Explanations

Attention measures coverage volume, not quality

Roivant Sciences's 50.9% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Roivant Sciences in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Scynexis's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 42/100 score.

Open Scynexis in Companies Radar
Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.
Coming soon